Please login to the form below
Symtuza
This page shows the latest Symtuza news and features for those working in and with pharma, biotech and healthcare.
Janssen’s single tablet Symtuza gains NHS England funding
Janssen and Gilead combination first to reach patients. J anssen has gained NHS England funding for its HIV treatment combination Symtuza, which combines a four drug regimen in a single tablet. ... The ruling puts Symtuza ahead of newly EU-approved
Latest news
-
Positive trial results for Janssen’s Symtuza boosts its HIV credentials
The STR provided ‘effective’ and ‘durable’ viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV
-
Janssen wins European approval for Symtuza
European Commission approves the drug to treat HIV-1. The European Commission (EC) has approved Janssen’s Symtuza (darunavir-STR) to treat adults with human immunodeficiency virus type 1 (HIV-1). ... Janssen can now market Symtuza in all countries in
-
CHMP backs three immuno-oncology drugs for solid tumours
Away from the cancer field, Johnson &Johnson's Janssen pharma unit got a positive opinion for Symtuza, the first complete, single-tablet HIV regimen based on its big-selling protease inhibitor
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
